Data_Sheet_1_The impact of the COVID-19 pandemic on palliative care practice: A survey of clinical oncologists.pdf

BackgroundPalliative care is an essential intervention to improve the quality of life for patients with cancer, whereas the ongoing COVID-19 pandemic poses a challenge to supportive and palliative care providers. This survey aims to explore the current status of palliative care practice for cancer and the influence of COVID-19, from the perspective of oncologists.MethodsThe semi-structure electronic questionnaire was designed. Mixed-mode surveys including electronic questionnaires, face-to-face interactions, and telephone interviews were adopted according to the willingness of respondents. Face-to-face and telephone interviews were based on same questions in the online questionnaire. Participants working in cancer-related departments with frontline palliative care experience during the COVID-19 outbreak were included. Surveys covered experiences and perspectives regarding the impact of COVID-19 on clinical work, personal lives, and palliative care practice. Suggestions on coping strategies were further proposed and qualitatively analyzed.ResultsThirty-seven oncologists participated in this study from September 2021 to January 2022. The majority of them believed COVID-19 significantly and negatively affected their clinical work routines (75.7%), personal daily lives (67.6%), and palliative care practice (64.9%). Most specialists considered that currently the palliative care system remained underdeveloped (73.0%), and other factors besides COVID-19 were associated with this situation (78.4%). Seventeen participants further made suggestions on how to promote palliative care during COVID-19, and three themes emerged through the qualitative analysis: (1) Remote or online service (88.2%); (2) Publicity, education, or shared decision-making for patients (29.4%); (3) Guidelines, training, or programs for care providers (23.6%).ConclusionOncologists consider that COVID-19 has an adverse impact on their palliative care practice and daily routine. In addition to COVID-19, other factors affecting palliative care should not be neglected. Corresponding measures are warranted to encourage palliative care practice during COVID-19.</p

Kaplan-Meier analyses of overall survival (OS), progression-free survival (PFS), distant metastasisfree survival (DMFS) and local-regional control (LRC) according to the microRNA signature in the testing data set (40 SCLC patients).

<p>Kaplan-Meier analyses of overall survival (OS), progression-free survival (PFS), distant metastasisfree survival (DMFS) and local-regional control (LRC) according to the microRNA signature in the testing data set (40 SCLC patients).</p

microRNAs associated with overall survival in SCLC.

<p>microRNAs associated with overall survival in SCLC.</p

Correlation between RT-PCR Ct and log 2-transformed array signal intensity values for (A) miR-150 and (B) miR-886-3p.

<p>(C) Correlation between expression of U6 RNA by qRT-PCR and log 2-transformed global mean array expression. (D) Expression of U6 RNA in human normal lung (NL, n = 3) and small-cell lung cancer (SCLC, n = 42) samples by microarray method. Whiskers depict the 10 and 90 percentiles. p value is calculated by the Mann-Whitney U test.</p

Multivariate Cox regression analysis of miRNA signature and survival in the testing set (N = 40).

<p>Multivariate Cox regression analysis of miRNA signature and survival in the testing set (N = 40).</p

Comparison of expression levels of miR-886-3p and miR-150 between SCLC tumors and normal lung tissues (NL).

<p>Comparison of expression levels of miR-886-3p and miR-150 between SCLC tumors and normal lung tissues (NL).</p

Clinical characteristics of the LD-SCLC patients.

<p>LD, limited stage disease; SCLC, small cell lung cancer; No, number; ChT, chemotherapy; OS, overall survival; PFS, progression-free survival; LRC, local-regional control; DMFS, distant metastasis-free survival; NR, not reached.</p

Kaplan-Meier analyses of overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS) and local-regional control (LRC) according to the microRNA signature in the training data set (42 SCLC patients).

<p>Kaplan-Meier analyses of overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS) and local-regional control (LRC) according to the microRNA signature in the training data set (42 SCLC patients).</p

Additional file 1 of MR radiomics predicts pathological complete response of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a multicenter study

Supplementary Material

DataSheet_1_Efficacy and safety of definitive chemoradiotherapy with or without induction immune checkpoint inhibitors in patients with stage III non-small cell lung cancer.docx

BackgroundIn the era of immunotherapy, the optimal combination of immune checkpoint inhibitors (ICIs) and chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) is not defined. The current study investigated the efficacy and safety of definitive CRT(dCRT) plus consolidation ICIs with or without induction ICIs in stage III NSCLC.Methods123 consecutive patients treated with dCRT followed by consolidation ICIs at our institution from 2018 to 2022 were retrospectively reviewed. Failure patterns, survival outcomes, and toxicity profiles were analyzed.ResultsThe 1- and 2- year PFS rates were 75.3% and 56.9%, respectively, and median PFS was 30.83 months from the start of treatment. In-field failure (18.7%) was the most common failure pattern. The most common adverse event (AE) was pneumonitis caused by ICIs or RT. The incidence of Grade 3-4 and Grade 5 pneumonitis was 5.7% and 1.6%, respectively. Further analysis showed that the induction plus consolidation ICIs group has significantly lower cumulative incidence of distant metastasis rates (HR: 0.30, 95%CI: 0.09-1.00, p=0.043) and higher incidence of pneumonitis (p=0.039) compared with patients in the consolidation ICIs group.ConclusionsCombined CRT and consolidation ICIs achieved encouraging efficacy and manageable toxicity in patients with stage III NSCLC in China. Induction plus consolidation ICIs might reduce distant metastasis and deserve further investigation.</p